Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Tango Therapeutics Inc (TNGX)

Tango Therapeutics Inc (TNGX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,614,312
  • Shares Outstanding, K 142,689
  • Annual Sales, $ 62,380 K
  • Annual Income, $ -101,590 K
  • EBIT $ -110 M
  • EBITDA $ -111 M
  • 60-Month Beta 1.31
  • Price/Sales 55.03
  • Price/Cash Flow N/A
  • Price/Book 9.36

Options Overview Details

View History
  • Implied Volatility 116.66% (-22.43%)
  • Historical Volatility 104.23%
  • IV Percentile 5%
  • IV Rank 11.27%
  • IV High 777.13% on 05/12/25
  • IV Low 32.80% on 09/04/25
  • Expected Move (DTE 1) 0.00 (0.00%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 3
  • Volume Avg (30-Day) 134
  • Put/Call OI Ratio 0.60
  • Today's Open Interest 4,328
  • Open Int (30-Day) 3,607
  • Expected Range 25.26 to 25.26

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.33
  • Number of Estimates 6
  • High Estimate $-0.28
  • Low Estimate $-0.45
  • Prior Year $-0.36
  • Growth Rate Est. (year over year) +8.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
17.52 +43.44%
on 03/17/26
25.47 -1.33%
on 04/16/26
+7.25 (+40.55%)
since 03/16/26
3-Month
10.80 +132.69%
on 03/02/26
25.47 -1.33%
on 04/16/26
+12.12 (+93.16%)
since 01/16/26
52-Week
1.03 +2,339.81%
on 05/08/25
25.47 -1.33%
on 04/16/26
+23.85 (+1,863.28%)
since 04/16/25

Most Recent Stories

More News
Tango Therapeutics Announces Leadership Appointments to Accelerate Late-Stage Development of Vopimetostat

-  Matthew Gall appointed Chief Financial Officer  - -  Additional key appointments add expertise in clinical operations, corporate strategy and project leadership  - BOSTON, April 15, 2026...

TNGX : 25.39 (+0.24%)
This Stock Is Up 1,229% in Just the Past Year, But Don’t Bet Your Retirement Money on It

Tango Therapeutics (TNGX) has surged 1,229% over the past year. Shares are trading at a new all-time high and have strong technical momentum. TNGX maintains a 100% “Buy” technical opinion from Barchart....

TNGX : 25.39 (+0.24%)
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, March 06, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that, effective February 2, 2026, the Compensation Committee of Tango Therapeutics' Board of Directors...

TNGX : 25.39 (+0.24%)
Tango Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights

Initial Phase 1/2 trial data of vopimetostat in combination with Revolution Medicines’ RAS(ON) inhibitors in MTAP-deleted pancreatic cancer in 2026 with continued robust patient enrollment New clinical...

TNGX : 25.39 (+0.24%)
Tango Therapeutics to Report Fourth Quarter 2025 Financial Results and Participate in Three Upcoming Investor Conferences

BOSTON, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that it will report fourth quarter 2025 financial results on March 5, 2026, before the open of the U.S....

TNGX : 25.39 (+0.24%)
Tango Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

BOSTON, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that Malte Peters, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to...

TNGX : 25.39 (+0.24%)
Tango Therapeutics Announces CEO Transition: Barbara Weber to Retire, Malte Peters Appointed Successor

Founding CEO Barbara Weber, M.D. to become executive chair of the board of directors Malte Peters, M.D., current board member, appointed President and Chief Executive Officer, effective immediately...

TNGX : 25.39 (+0.24%)
Tango Therapeutics Appoints Sung Lee to Board of Directors

BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer...

TNGX : 25.39 (+0.24%)
Tango Therapeutics to Participate in 44th Annual J.P. Morgan Healthcare Conference

BOSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled...

TNGX : 25.39 (+0.24%)
Tango Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference

BOSTON, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that Adam Crystal, M.D., Ph.D., President of Research & Development at Tango Therapeutics, is scheduled...

TNGX : 25.39 (+0.24%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength is above 70%. The market is in overbought territory. Watch for a potential trend reversal.

See More Share

Business Summary

Tango Therapeutics Inc. is a biotechnology company. It focused on discovering and delivering precision cancer medicines. Tango Therapeutics Inc., formerly known as BCTG Acquisition Corp., is based in CAMBRIDGE, Mass.

See More

Key Turning Points

3rd Resistance Point 27.50
2nd Resistance Point 26.46
1st Resistance Point 25.89
Last Price 25.39
1st Support Level 24.28
2nd Support Level 23.24
3rd Support Level 22.67

See More

52-Week High 25.47
Last Price 25.39
Fibonacci 61.8% 16.13
Fibonacci 50% 13.25
Fibonacci 38.2% 10.37
52-Week Low 1.03

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.